Research · PMID 41909366 · Landmark study
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap.
Cureus · February 2026 · Andres F Quimbayo-Cifuentes
What this study found
The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists targeting both the GIP and GLP-1 receptors (GIP/GLP-1 dual agonists) has reshaped obesity management, approaching degrees of weight loss previously achievable largely through metabolic surgery. However, randomized withdrawal trials, including Semaglutide Treatment Effect in People with Obesity (STEP) 4 and SURMOUNT 4, show that discontinuation of GLP-1-based therapy is consistently followed by rapid weight regain (typically observed within one year of withdrawal) and a decline in cardiometabolic benefits.
Why this trial matters
GLP-1 weight regain after discontinuation
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Primary study
Do patients regain weight after stopping GLP-1 therapy?
Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.
Open evidence analysisSupporting literature
Does GLP-1 treatment cause meaningful muscle loss?
GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.
Open evidence analysisSupporting literature
Do GLP-1 receptor agonists reduce major cardiovascular events?
GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.
Open evidence analysisSupporting literature
Do GLP-1 agonists increase pancreatitis risk?
Early signals raised pancreatitis concern, but large trials and post-marketing data have not confirmed a strong causal increase at population level. Caution remains reasonable in patients with prior pancreatitis.
Open evidence analysisSupporting literature
Do GLP-1 drugs increase thyroid cancer risk in humans?
Rodent C-cell tumor signals led to contraindications in medullary thyroid carcinoma and MEN2. Human epidemiologic data have not established a clear excess of thyroid cancer, but long-term surveillance continues.
Open evidence analysisSupporting literature
How does tirzepatide compare with semaglutide for weight loss?
Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.
Open evidence analysisSupporting literature
Can resistance training and protein intake preserve muscle during GLP-1 weight loss?
Exercise and higher protein intake are biologically plausible strategies to attenuate lean mass loss during significant GLP-1-mediated weight reduction, though dedicated outcome trials are still emerging.
Open evidence analysis